Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Ovarian Cancer, Peritoneal Primary Cancer, Fallopian Tube Cancer
About this trial
This is an interventional supportive care trial for Ovarian Cancer focused on measuring stage I ovarian epithelial cancer, stage II ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, peritoneal cavity cancer
Eligibility Criteria
Inclusion Criteria: Newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer, any pathologic type or stage, who will receive 6 cycles of chemotherapy. Patients must have signed an informed consent Exclusion Criteria: Previous cancer other than skin cancer Previous chemotherapy experience Active substance abuse Schizophrenia Pregnant or lactating
Sites / Locations
- Masonic Cancer Center at University of Minnesota
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Chemotherapy Alone
Standard Chemotherapy + CAM
Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or primary peritoneal cancer by their treating physician. Chemotherapy administration is not administered as part of this protocol.
Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or peritoneal cancer with additional complementary alternative medicine - CAM (healing touch, hypnosis and massage therapy). Chemotherapy administration is not administered as part of this protocol.